Latest news with #PhaseIIItrial
Yahoo
7 days ago
- Business
- Yahoo
Viatris' blepharitis ointment fails Phase III trial
Viatris' investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug's future. The Phase III study (NCT06400511) evaluated the efficacy and safety of MR-139 (pimecrolimus 0.3%) ophthalmic ointment in 477 patients with the condition. Blepharitis usually affects both eyes along the edges of the eyelids and results from clogged oil glands at the base of the eyelashes. The study failed to reach the primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. After the failure was announced, Viatris' stock dropped 4.2%, from $9.27 at market close on 17 July to $8.88 at market close on 18 July. The US company has a market cap of $10.42bn. Viatris' chief R&D officer Philippe Martin said the company is currently working out the next steps for MR-139 in blepharitis. Martin said: "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase III programme, which may include revising the planned additional Phase III study.' A cream formulation of pimecrolimus, marketed as Eildel, was approved in 2001 for use in a number of dermatology indications by Novartis. Generics have since been approved by companies, including Teva Pharmaceuticals and Glenmark Therapeutics. The therapy has not been approved in any ophthalmology indications. Last month, the company's phentolamine ophthalmic solution 0.75% was successful in a second Phase III presbyopia study, with the company eyeing FDA approval of the therapy. In the same month, Viatris also had success in the Phase III LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Approved treatments for blepharitis include steroid eyedrops and topical antibiotics; however, in some circumstances, oral antibiotics may also be prescribed. For Demodex blepharitis, Tarsus Pharmaceuticals' Xdemvy (lotilaner ophthalmic solution) is prescribed to target and eliminate the mites on the eyelashes responsible for the condition. GlobalData predicts Xdemvy to reach blockbuster status in 2030, with a global sales forecast of $1.03bn. GlobalData is the parent company of Clinical Trials Arena. "Viatris' blepharitis ointment fails Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
14-07-2025
- Business
- Yahoo
AstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension Trial
AstraZeneca recently experienced a weekly price move of 2% amid announcements that could have supported its momentum. The successful Phase III trial results for Baxdrostat, targeting a significant global need for hypertension treatments, likely provided a positive catalyst. Additionally, the European Union's approval of Imfinzi for a new cancer indication may have added further support. These developments occurred against a backdrop of flat overall market performance, with major indexes barely changing as global investors assessed trade policy uncertainties and awaited key financial data releases. We've identified 3 warning signs with AstraZeneca and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent developments for AstraZeneca, particularly the successful Phase III trial results for Baxdrostat and the EU's approval of Imfinzi, could significantly enhance the company's revenue and earnings forecasts. These breakthroughs address substantial medical needs in hypertension and cancer, potentially expanding AstraZeneca's market share and boosting prescription sales. Combined with AstraZeneca's global strategic initiatives, these news items reinforce the company's narrative of growth through innovation and market expansion. Over the past five years, AstraZeneca has achieved a total shareholder return of 25.87%. This long-term performance provides a broader context compared to the recent weekly share price movement of 2%. While AstraZeneca underperformed both the UK market with a return of 5.9% and the UK Pharmaceuticals industry with a negative return of 9.3% over the past year, the strong long-term total returns highlight the company's resilience and potential for enduring growth. As analysts have set a price target of £135.83, approximately 30% above the current share price of £107.28, these recent developments may positively influence future investor sentiment. The new advancements in AstraZeneca's product pipeline and expansion in emerging markets bolster the expectation of future revenue, aligning with analysts' forecasts of significant earnings improvements over the next few years. The current share price discount to the analyst price target could suggest that the market has not yet fully realized the potential upside of these recent achievements. Gain insights into AstraZeneca's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
